OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

September 29, 2025

RE: Testosterone Products, Opioid Analgesics/Medication Assisted Treatment (MAT) Medications, and Jynarque® (Tolvaptan) Coverage Changes Effective October 13, 2025

The following changes will take effect on October 13, 2025. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy prior authorization forms can be found on the OHCA website at https://oklahoma.gov/ohca/rxforms.

Testosterone Products

Changes to the Testosterone Products tier chart include the following:

- **Testosterone topical gel 1% packets and tube (generic Testim®, Vogelxo®) and testosterone topical solution (generic Axiron®)** will move to Tier-2. Members currently utilizing testosterone 1% packets or tubes or testosterone topical solution will need to submit a PA request for a Tier-1 alternative. The topical Tier-1 alternative is testosterone topical gel 1.62% pump (generic Androgel®).

The specific PA requirements and tier chart for the Testosterone Products can be found on the OHCA website in the "Diabetes/Endocrine" therapeutic category.

Opioid Analgesics/MAT Medications

Changes to the Opioid Analgesics tier chart include the following:

- **Hysingla® ER (hydrocodone ER tablet)** will become brand preferred. Members currently utilizing generic hydrocodone ER will need to switch to brand Hysingla® ER.
- **RoxyBond™ (oxycodone tablet)** will move to the Special PA tier.

Changes to the MAT Medications coverage include the following:

- **Buprenorphine sublingual tablets (generic Subutex®)** will no longer require a PA. A quantity limit of 90 tablets per 30 days will still apply.

The specific PA requirements and tier chart for the Opioid Analgesics/MAT Medications can be found on the OHCA website in the "Central Nervous System/Behavioral Health" therapeutic category.

Jynarque® (Tolvaptan)

Jynarque® will become brand preferred. Members currently utilizing generic tolvaptan will need to switch to brand Jynarque®. The specific PA requirements for Jynarque® can be found on the OHCA website in the "Genetic Disorders" therapeutic category.

Thank you for the services you provide to Oklahomans insured by SoonerCare!